相关实验视频

Updated: Jan 13, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

确定CBFA2T3::GLIS2急性髓性白血病的向治疗方法

Fanny Gonzales^1,2,3, Constanze Schneider^4,5, Gabriela Alexe^4,5

¹Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA, USA. fanny.gonzales@unige.ch.

|January 8, 2026

概括

儿童急性髓性白血病 (AML) 与CBFA2T3::GLIS2融合高度依赖于JAK2. 将JAK2抑制剂与MEK抑制剂结合起来,有望治疗这种侵袭性AML亚型.

科学领域:

在瘤学瘤学.
血液学血液学血液学
遗传学是一个遗传学.

背景情况:

CBFA2T3::GLIS2阳性儿科急性髓性白血病 (AML) 是一个具有不良预后的高风险亚组.
确定新的治疗点对于改善这种AML亚型的结果至关重要.

研究的目的:

为了发现CBFA2T3::GLIS2-阳性AML的创新向治疗方法.
调查对JAK2的依赖以及对JAK2抑制剂耐药性的机制.

主要方法:

基因组规模的CRISPR-Cas9查以确定依赖性.
用多西环素诱导的JAK2淘汰系统进行验证.
通过CRISPR-Cas9 ruxolitinib选,以确定耐药性机制.
在细胞系和患者衍生异种移植 (PDX) 中使用JAK2和MEK抑制剂进行组合疗法研究.

主要成果:

基因组规模查显示,CBFA2T3::GLIS2 AML.中的JAK2具有选择性依赖性.
在体外和体内,JAK2抑制损害了增殖和诱导了亡.
由NRAS突变驱动的MAPK通路激活,成为对JAK2抑制剂的抵抗机制.
卢克索利提尼布 (JAK2 抑制剂) 和MEK 抑制剂的组合显示出协同效应和体内活性.

结论:

CBFA2T3::GLIS2 AML 严重依赖于 JAK2 信号传递.
MAPK通路的激活赋予了对JAK2抑制剂的耐药性.
针对JAK2和MAPK通路的组合疗法为这种预后不佳的AML亚型提供了潜在的治疗策略.

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...